The role of cytokines in classical Hodgkin lymphoma

Blood

Volumn 99, Issue 12, 2002, Pages 4283-4297

  Skinnider, Brian F ^a   Mak, Tak W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 LIGAND; CD40 LIGAND; CHEMOKINE; CHEMOKINE MIG; CYTOKINE; EOTAXIN; FAS ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; LIGAND; LYMPHOTOXIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CELL GROWTH; CELL LINE; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; EOSINOPHIL; EPSTEIN BARR VIRUS; FIBROBLAST; HODGKIN DISEASE; HUMAN; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

EID: 0037097818     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0099     Document Type: Review

References (187)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
2. Hodgkin lymphoma
3. Recent results on the biology of Hodgkin and Reed-Sternberg cells, II: Continuous cell lines
4. The nature of Reed-Sternberg cells, lymphocytic and histiocytic cells and their molecular biology in Hodgkin's disease
5. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells
6. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient
7. Single-cell analysis of Hodgkin and Reed-Sternberg cells: Molecular heterogeneity of gene expression and p53 mutations
8. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
9. Interleukin-4: A prototypic immunoregulatory lymphokine
10. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells
11. Production of multiple cytokines by Hodgkin's disease derived cell lines
12. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease
13. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease
14. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
15. Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed-Sternberg cell
16. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth
17. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease
18. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells
19. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
20. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: Possible autocrine mechanism and involvement in fibrosis
21. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist
22. Interleukin-5, eosinophils, and disease
23. Detection of Interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia
24. Interleukin-6 family of cytokines and gp130
25. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease
26. Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases
27. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus
28. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: Comparison with Hodgkin's disease
29. STAT3 is constitutively activated in Hodgkin cell lines
30. Role of IL-9 in the pathophysiology of allergic diseases
31. Interleukin-9 expression in human malignant lymphomas: Unique association with Hodgkin's disease and large cell anaplastic lymphoma
32. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines
33. Interleukin-10 and the interleukin-10 receptor
34. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
35. Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders
36. Interleukin-2: Inception, impact, and implications
37. Expression of p55 (Tac) interleukin-2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and H-RS cells in tissues
38. High affinity IL-2 receptors on a Hodgkin's derived cell line
39. The IL-2 receptor complex: Its structure, function, and target genes
40. Immunoprecipitation of the interleukin-2 receptor from Hodgkin's disease derived cell lines by monoclonal antibodies
41. Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease
42. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases
43. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases
44. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's disease using fixed frozen tissues
45. Production of transforming growth factor-beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth
46. Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells. Comparison with effects of phorbol ester and retinoic acid
47. The molecular cell biology of interferon-gamma and its receptor
48. Immunoenzymatic assessment of interferon-gamma in Hodgkin and Sternberg-Reed cells
49. Differential chemokine expression in tissues involved by Hodgkin's disease: Direct correlation of eotaxin expression and tissue eosinophilia
50. Chemokines: A new classification system and their role in immunity
51. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
52. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine
53. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma
54. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma
55. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: Application of tissue microarrays
56. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils
57. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease
58. Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density
59. The TNF and TNF receptor superfamilies: Integrating mammalian biology
60. Tumor necrosis factor receptor and Fas signaling mechanisms
61. Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2
62. Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease
63. Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients
64. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study
65. In situ expression of the IL-1-alpha and TNF-alpha genes by Reed-Sternberg cells in Hodgkin's disease
66. Interleukin-1 and tumor necrosis factor-alpha in the Reed-Steinberg cells of Hodgkin's disease. Correlation with clinical and morphological "inflammatory" features
67. Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha
68. The CD40 antigen and its ligand
69. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease
70. CD40 expression in Hodgkin's disease
71. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease
72. Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus injection
73. CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line
74. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study
75. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease
76. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: Expression and cellular localization of EBV gene products
77. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses
78. Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling
79. Tumor necrosis factor receptor-associated factors (TRAFs) - A family of adapter proteins that regulates life and death
80. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
81. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines
82. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues
83. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: Distinction between Hodgkin's disease and anaplastic large cell lymphoma
84. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line
85. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease
86. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
87. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines
88. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells
89. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines
90. Interleukin-1
91. Heterogeneity of interleukin 1 production in cultured Reed-Sternberg cell lines HDLM-1, HDLM-1d, and KM-H2
92. Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from true histiocytic malignancies
93. Anti-interleukin-1 reactive cells in Hodgkin's disease
94. Transforming growth factor-beta and its receptors
95. L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH
96. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease
97. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease
98. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease
99. Cytokines in hematopoiesis
100. Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease
101. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants
102. Immunohistochemical detection of cells positive for colony-stimulating factor 1 in lymph nodes from reactive lymphadenitis, and Hodgkin's disease
103. Expression of membrane-associated macrophage colonystimulating factor (M-CSF) in Hodgkin's disease and other hematologic malignancies
104. Lack of CSF-1 receptor message in Reed-Sternberg cells
105. Jaks and STATs: Biological implications
106. The biology of Stat4 and Stat6
107. Essential role of Stat6 in IL-4 signalling
108. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells
109. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice
110. Cutting edge: Differential expression of chemokines in Th1 and Th2 cells is dependent on Stat6 but not Stat4
111. Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation
112. STATs in oncogenesis
113. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells
114. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
115. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells
116. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response
117. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
118. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells
119. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells
120. Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease
121. Aberrant rel/nfkb genes and activity in human cancer
122. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
123. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells
124. Highlevel nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells
125. Defective IkappaB-alpha in Hodgkin cell lines with constitutively active NF-kappaB
126. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells
127. Characterization of NF-kappaB expression in Hodgkin's disease: Inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells
128. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
129. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells
130. Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H 12
131. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaB-alpha
132. Clonal deleterious mutations in the IkappaB-alpha gene in the malignant cells in Hodgkin's lymphoma
133. Hodgkin disease: Pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor
134. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells
135. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function
136. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells
137. Interleukin 13 is a B cell stimulating factor
138. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease
139. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription
140. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death
141. Germinal centers
142. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/ CD40-L. Potential role in regulating helper effector function
143. + Th0, Th1 and Th2 T cell clones and EBV-transformed B cells
144. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-xL and Mcl-1
145. Eosinophilia
146. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism
147. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alphainduced fibroblasts
148. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production
149. In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease
150. Lymph node T cells in Hodgkin's disease: Analysis of suspensions with monoclonal antibody and rosetting techniques
151. T-lymphocyte subpopulations in B-cell-derived non-Hodgkin's lymphomas and Hodgkin's disease
152. B- and T-lymphocytes in Hodgkin's disease. An immunohistochemical study utilizing heterologous and monoclonal antibodies
153. Immune reactions in classical Hodgkin's lymphoma
154. Displacement of T lymphocytes with the "helper/inducer" phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin's disease
155. Amplification of TCR-beta gene rearrangements from micromanipulated single cells: T cells rosetting around Hodgkin and Reed-Sternberg cells in Hodgkin's disease are polyclonal
156. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13
157. Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: An amplification circuit of polarized T helper 2 responses
158. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells
159. CD8(+) T cells in Hodgkin's disease tumor tissue are a polyclonal population with limited clonal expansion but little evidence of selection by antigen
160. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease
161. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease
162. The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease
163. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease
164. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: Implications for a T-cell-based therapy
165. Potentiation of fibroblast growth by nodular sclerosing Hodgkin's disease cell cultures
166. Basic fibroblast growth factor and fibrosis in Hodgkin's disease
167. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor beta - Simultaneous application with basic fibroblast growth factor causes persistent fibrosis
168. Fibrosis of the lung and other tissues: New concepts in pathogenesis and treatment
169. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response
170. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent
171. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts
172. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)
173. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
174. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease
175. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease
176. Serum concentrations of cytokines in patients with Hodgkin's disease
177. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease
178. The impact of Hodgkin's disease on the immune system
179. Hyperproduction of IgE and T-cell dysfunction in Hodgkin's disease
180. Hypergammaglobulinaemia E in Hodgkin's disease and its relationship to atopy or a familial predisposition to atopy
181. Soluble cytokine receptors
182. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma
183. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome
184. Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis
185. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition
186. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer
187. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease